Effect of bovine lactoferrin on Chlamydia trachomatis infection and inflammation.

Chlamydia trachomatis is an obligate, intracellular pathogen responsible for the most common sexually transmitted bacterial disease worldwide, causing acute and chronic infections. The acute infection is susceptible to antibiotics, whereas the chronic one needs prolonged therapies, thus increasing the risk of developing antibiotic resistance. Novel alternative therapies are needed. The intracellular development of C. trachomatis requires essential nutrients, including iron. Iron-chelating drugs inhibit C. trachomatis developmental cycle. Lactoferrin (Lf), a pleiotropic iron binding glycoprotein, could be a promising candidate against C. trachomatis infection. Similarly to the efficacy against other intracellular pathogens, bovine Lf (bLf) could both interfere with C. trachomatis entry into epithelial cells and exert an anti-inflammatory activity. In vitro and in vivo effects of bLf against C. trachomatis infectious and inflammatory process has been investigated. BLf inhibits C. trachomatis entry into host cells when incubated with cell monolayers before or at the moment of the infection and down-regulates IL-6/IL-8 synthesized by infected cells. Six out of 7 pregnant women asymptomatically infected by C. trachomatis, after 30 days of bLf intravaginal administration, were negative for C. trachomatis and showed a decrease of cervical IL-6 levels. This is the first time that the bLf protective effect against C. trachomatis infection has been demonstrated.

[1]  J. Hegemann,et al.  The Chlamydia trachomatis Ctad1 invasin exploits the human integrin β1 receptor for host cell entry , 2016, Cellular microbiology.

[2]  Marleen Temmerman,et al.  Global Estimates of the Prevalence and Incidence of Four Curable Sexually Transmitted Infections in 2012 Based on Systematic Review and Global Reporting , 2015, PloS one.

[3]  K. Workowski,et al.  Sexually transmitted diseases treatment guidelines, 2015. , 2015, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[4]  Virginia Apgar.  A Proposal for a New Method of Evaluation of the Newborn Infant , 2015, Anesthesia and analgesia.

[5]  R. Ragno,et al.  Effects of Mentha suaveolens Essential Oil on Chlamydia trachomatis , 2015, BioMed research international.

[6]  S. Kohlhoff,et al.  Treatment of chlamydial infections: 2014 update , 2015, Expert opinion on pharmacotherapy.

[7]  E. McLaughlin,et al.  The Role of the Immune Response in Chlamydia trachomatis Infection of the Male Genital Tract: A Double-Edged Sword , 2014, Front. Immunol..

[8]  G. Schiavoni,et al.  Effects of vaginal lactobacilli in Chlamydia trachomatis infection. , 2014, International journal of medical microbiology : IJMM.

[9]  P. Valenti,et al.  Lactoferrin differently modulates the inflammatory response in epithelial models mimicking human inflammatory and infectious diseases , 2014, BioMetals.

[10]  R. Bastidas,et al.  Chlamydial intracellular survival strategies. , 2013, Cold Spring Harbor perspectives in medicine.

[11]  R. Sessa,et al.  New Insights into Chlamydiae Persistence: An Energy Metabolism Strategy? , 2013, International journal of immunopathology and pharmacology.

[12]  P. Valenti,et al.  Bovine lactoferrin in preventing preterm delivery associated with sterile inflammation. , 2012, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[13]  Bingyun Li,et al.  Nanomedicine as an emerging approach against intracellular pathogens , 2011, International journal of nanomedicine.

[14]  F. Pantanella,et al.  Lactoferrin Decreases Inflammatory Response by Cystic Fibrosis Bronchial Cells Invaded with Burkholderia Cenocepacia Iron-Modulated Biofilm , 2011, International journal of immunopathology and pharmacology.

[15]  Chengyu Jiang,et al.  Inhibition of SARS Pseudovirus Cell Entry by Lactoferrin Binding to Heparan Sulfate Proteoglycans , 2011, PloS one.

[16]  P. Valenti,et al.  Bovine Lactoferrin Counteracts Toll-Like Receptor Mediated Activation Signals in Antigen Presenting Cells , 2011, PloS one.

[17]  M. O’Sullivan,et al.  Public health policies and management strategies for genital Chlamydia trachomatis infection , 2011, Risk management and healthcare policy.

[18]  R. Carabeo,et al.  An Optimal Method of Iron Starvation of the Obligate Intracellular Pathogen, Chlamydia Trachomatis , 2011, Front. Microbio..

[19]  P. Wyrick.  Chlamydia trachomatis persistence in vitro: an overview. , 2010, The Journal of infectious diseases.

[20]  A. Schryvers,et al.  The N1 domain of human lactoferrin is required for internalization by caco-2 cells and targeting to the nucleus. , 2008, Biochemistry.

[21]  M. Ammendolia,et al.  Bovine Lactoferrin Inhibits the Efficiency of Invasion of Respiratory A549 Cells of Different Iron-Regulated Morphological Forms of Pseudomonas Aeruginosa and Burkholderia Cenocepacia , 2008, International journal of immunopathology and pharmacology.

[22]  G. Donnarumma,et al.  Lactoferrin downregulates pro-inflammatory cytokines upexpressed in intestinal epithelial cells infected with invasive or noninvasive Escherichia coli strains. , 2006, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[23]  P. Valenti,et al.  Lactoferrin: an important host defence against microbial and viral attack. , 2005, Cellular and molecular life sciences : CMLS.

[24]  B. Lönnerdal,et al.  Cellular internalization of lactoferrin in intestinal epithelial cells , 2004, Biometals.

[25]  F. Superti,et al.  Effect of bovine lactoferricin on enteropathogenic Yersinia adhesion and invasion in HEp-2 cells. , 2004, Journal of medical microbiology.

[26]  L. G. Giugliano,et al.  In vitro adhesion and invasion inhibition of Shigella dysenteriae, Shigella flexneri and Shigella sonnei clinical strains by human milk proteins , 2004, BMC Microbiology.

[27]  P. Timms,et al.  Chlamydial Persistence: beyond the Biphasic Paradigm , 2004, Infection and Immunity.

[28]  Gale R. Burstein,et al.  Sexually transmitted diseases treatment guidelines , 2003, Current opinion in pediatrics.

[29]  G. Zhong,et al.  Genomic transcriptional profiling of the developmental cycle of Chlamydia trachomatis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Christina H. Park,et al.  Antimicrobial components of vaginal fluid. , 2002, American journal of obstetrics and gynecology.

[31]  T. Meyer,et al.  Low iron availability modulates the course of Chlamydia pneumoniae infection , 2001, Cellular microbiology.

[32]  J. Raulston.  Response of Chlamydia trachomatis serovar E to iron restriction in vitro and evidence for iron-regulated chlamydial proteins , 1997, Infection and immunity.

[33]  D. Monroe,et al.  Characterization of the glycosaminoglycan-binding region of lactoferrin. , 1995, Archives of biochemistry and biophysics.

[34]  A. Alfsen,et al.  Influence of lactoferrin on the entry process of Escherichia coli HB101(pRI203) in HeLa cells , 1993, Medical Microbiology and Immunology.

[35]  E. Schonne,et al.  LACTOFERRIN, AN IRON-BINBING PROTEIN NI NEUTROPHILIC LEUKOCYTES , 1969, The Journal of experimental medicine.

[36]  P. Valenti,et al.  Anti-invasive activity of bovine lactoferrin towards group A streptococci. , 2002, Biochemistry and cell biology = Biochimie et biologie cellulaire.